Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Generation IM’s Q2 2025 portfolio value declined to $15.73B, with 37 positions. Click here to read more about the portfolio's ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

A new Equifax® (NYSE:EFX) survey shows that human resources (HR) leaders are facing challenges using technology innovation to ...

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH ...

Shares of Equifax Inc. EFX slid 2.06% to $248.07 Thursday, on what proved to be an all-around mixed trading session for the ...

A number of stocks jumped in the afternoon session after markets continued to rally as investor optimism grew for a potential ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

Quality boots, weather systems, and field accessories were among the highlights of this year's product launches. Here’s what ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...